MA47121A - Molécules de liaison pour le traitement du cancer - Google Patents
Molécules de liaison pour le traitement du cancerInfo
- Publication number
- MA47121A MA47121A MA047121A MA47121A MA47121A MA 47121 A MA47121 A MA 47121A MA 047121 A MA047121 A MA 047121A MA 47121 A MA47121 A MA 47121A MA 47121 A MA47121 A MA 47121A
- Authority
- MA
- Morocco
- Prior art keywords
- binding molecules
- cancer treatment
- cancer
- treatment
- molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437770P | 2016-12-22 | 2016-12-22 | |
| EP17155973.5A EP3360898A1 (fr) | 2017-02-14 | 2017-02-14 | Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47121A true MA47121A (fr) | 2019-10-30 |
Family
ID=58043942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047121A MA47121A (fr) | 2016-12-22 | 2017-12-21 | Molécules de liaison pour le traitement du cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10858438B2 (fr) |
| EP (2) | EP3360898A1 (fr) |
| JP (1) | JP7196076B2 (fr) |
| KR (1) | KR102651761B1 (fr) |
| CN (1) | CN110582513B (fr) |
| AU (1) | AU2017384687B2 (fr) |
| BR (1) | BR112019011750A2 (fr) |
| CA (1) | CA3046591A1 (fr) |
| CO (1) | CO2019006320A2 (fr) |
| EA (1) | EA201991480A1 (fr) |
| MA (1) | MA47121A (fr) |
| MX (1) | MX391650B (fr) |
| PE (1) | PE20191251A1 (fr) |
| TW (1) | TWI790219B (fr) |
| WO (1) | WO2018115231A2 (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3360898A1 (fr) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer |
| US20210115152A1 (en) * | 2018-05-16 | 2021-04-22 | Arbele Limited | Composition of bispecific antibodies and method of use thereof |
| EP3725370A1 (fr) * | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Anticorps anti-pd-l1 modifiés et procédés et utilisations pour le traitement d'une maladie neurodégénérative |
| JP2023526223A (ja) * | 2020-05-11 | 2023-06-21 | クリーブ セラピューティクス，インク． | がん処置のためのＶＣＰ／ｐ９７阻害薬 |
| CA3180665A1 (fr) * | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Molecules de liaison pour le traitement du cancer |
| WO2022155518A1 (fr) | 2021-01-15 | 2022-07-21 | Seagen Inc. | Conjugués anticorps-médicament immunomodulateurs |
| MX2023009113A (es) | 2021-02-03 | 2023-08-10 | Seagen Inc | Conjugados y compuestos inmunoestimulantes. |
| CN117813120A (zh) * | 2021-06-07 | 2024-04-02 | 旗舰先锋创新Vii有限责任公司 | 用于靶向递送治疗剂的组合物和方法 |
| CN113512117B (zh) * | 2021-07-12 | 2023-08-22 | 武汉麦考津生物科技有限公司 | 一种可结合cd206的抗体及其应用 |
| US20250270314A1 (en) * | 2021-08-02 | 2025-08-28 | Tavotek Biotech (Suzhou) Ltd | Anti-cdh17 monoclonal and bispecific antibodies and uses thereof |
| WO2023023677A1 (fr) * | 2021-08-20 | 2023-02-23 | University Of Virginia Patent Foundation | Stratégie pour l'activation de dr5 hautement supérieure, notamment dans des tumeurs et des cancers |
| CA3252067A1 (fr) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Conjugués anticorps-médicament immunomodulateurs |
| EP4554677A1 (fr) | 2022-07-15 | 2025-05-21 | Boehringer Ingelheim International GmbH | Molécules de liaison pour le traitement du cancer |
| AU2023320054A1 (en) | 2022-08-03 | 2025-02-06 | Regents Of The University Of Minnesota | Immunostimulatory anti-pd-l1-drug conjugates |
| EP4321522A1 (fr) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Composés cytotoxiques et conjugués de ceux-ci |
| CN120359047A (zh) * | 2022-10-14 | 2025-07-22 | 旗舰创业创新第七有限责任公司 | 用于靶向递送治疗剂的组合物和方法 |
| CN115785269B (zh) * | 2022-11-01 | 2023-09-22 | 四川大学 | 抗pd-l1的抗体及其应用 |
| AU2023375570A1 (en) | 2022-11-10 | 2025-06-12 | Immuvia Inc | Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof |
| CN120712286A (zh) | 2023-02-23 | 2025-09-26 | 翰森生物有限责任公司 | 抗体、抗原结合片段和使用方法 |
| WO2025072182A2 (fr) * | 2023-09-25 | 2025-04-03 | Trio Pharmaceuticals, Inc. | Activation ciblée de mort cellulaire endogène |
| WO2025108446A1 (fr) * | 2023-11-23 | 2025-05-30 | LaNova Medicines Limited | Anticorps anti-cdh17 et leurs conjugués |
| WO2025242099A1 (fr) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | Conjugué anticorps-médicament contre cdh17 et son utilisation |
| WO2025261505A1 (fr) * | 2024-06-21 | 2025-12-26 | 映恩生物制药（苏州）有限公司 | Conjugué médicament-anticorps anti-cdh17 et son utilisation |
| WO2026017120A1 (fr) * | 2024-07-18 | 2026-01-22 | 信达生物制药(苏州)有限公司 | Anticorps trispécifique anti-cdh17/egfr/cd16a et son utilisation |
| WO2026020031A2 (fr) | 2024-07-18 | 2026-01-22 | Novarock Biotherapeutics, Ltd. | Anticorps cdh17 et leurs utilisations |
| WO2026046327A1 (fr) * | 2024-08-29 | 2026-03-05 | Utc Therapeutics (Shanghai) Co., Ltd. | Anticorps ciblant cdh17, récepteurs antigéniques chimériques et leurs utilisations |
| CN119310289A (zh) * | 2024-10-31 | 2025-01-14 | 新疆维吾尔自治区人民医院 | On的检测试剂在辅助诊断急性胸痛疾病中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US168A (en) | 1837-04-17 | Improvement in fire-arms | ||
| US5731A (en) | 1848-08-22 | Elisha k | ||
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1988001649A1 (fr) | 1986-09-02 | 1988-03-10 | Genex Corporation | Molecules de liaison de chaines de polypeptide simples |
| EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| AU7266698A (en) | 1997-04-30 | 1998-11-24 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| EP1274720A4 (fr) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | Proteines fusionnees a l'albumine |
| CN101684158A (zh) | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| US20050214857A1 (en) | 2001-12-11 | 2005-09-29 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| EP1465925A4 (fr) | 2001-12-20 | 2006-02-08 | Human Genome Sciences Inc | Anticorps se liant de maniere immunospecifique a des recepteurs trail |
| EP1600459A3 (fr) | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| EP2284192A3 (fr) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Anticorps de Camelidae pour administration sublinguale |
| SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
| US20050079184A1 (en) | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| US20060228352A1 (en) | 2005-02-24 | 2006-10-12 | Schoenberger Stephen P | TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL |
| PL2860192T3 (pl) | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| EP3663318A1 (fr) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique |
| EP3009454A3 (fr) | 2009-04-20 | 2016-10-19 | Oxford Bio Therapeutics Limited | Anticorps spécifiques à la cadhérine-17 |
| KR101508043B1 (ko) | 2009-09-29 | 2015-04-06 | 로슈 글리카트 아게 | 이중특이적 사멸 수용체 아고니스트성 항체 |
| NZ610091A (en) * | 2010-10-20 | 2015-02-27 | Oxford Biotherapeutics Ltd | Antibodies |
| US20130025987A1 (en) | 2011-07-18 | 2013-01-31 | David Batterbee | Methods and apparatus for controlling a fluid damper |
| EP2684896A1 (fr) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anticorps de la famille anti-DR5 ou bispécifique anticorps de la famille anti-DR5 multivalents et leurs procédés d'utilisation |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| NO2776305T3 (fr) | 2014-04-23 | 2018-01-27 | ||
| PE20170903A1 (es) | 2014-08-12 | 2017-07-12 | Novartis Ag | Conjugados de farmacos con anticuerpos anti-cdh6 |
| PE20170912A1 (es) | 2014-11-14 | 2017-07-12 | Novartis Ag | Conjugados de anticuerpo-farmaco |
| JP7179464B2 (ja) * | 2015-01-20 | 2022-11-29 | アイジーエム バイオサイエンシズ インコーポレイテッド | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 |
| HK1247215A1 (zh) | 2015-01-26 | 2018-09-21 | Macrogenics, Inc. | 包含dr5-结合结构域的多价分子 |
| UA127200C2 (uk) | 2016-05-18 | 2023-06-07 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Молекула антитіла до pd1 |
| EP3360898A1 (fr) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer |
-
2017
- 2017-02-14 EP EP17155973.5A patent/EP3360898A1/fr not_active Withdrawn
- 2017-12-21 EP EP17838041.6A patent/EP3559040B1/fr active Active
- 2017-12-21 TW TW106144948A patent/TWI790219B/zh active
- 2017-12-21 AU AU2017384687A patent/AU2017384687B2/en not_active Expired - Fee Related
- 2017-12-21 US US15/850,895 patent/US10858438B2/en active Active
- 2017-12-21 KR KR1020197018925A patent/KR102651761B1/ko active Active
- 2017-12-21 MX MX2019007511A patent/MX391650B/es unknown
- 2017-12-21 CA CA3046591A patent/CA3046591A1/fr active Pending
- 2017-12-21 PE PE2019001228A patent/PE20191251A1/es unknown
- 2017-12-21 WO PCT/EP2017/084002 patent/WO2018115231A2/fr not_active Ceased
- 2017-12-21 CN CN201780085628.8A patent/CN110582513B/zh active Active
- 2017-12-21 EA EA201991480A patent/EA201991480A1/ru unknown
- 2017-12-21 JP JP2019534104A patent/JP7196076B2/ja active Active
- 2017-12-21 BR BR112019011750-4A patent/BR112019011750A2/pt active Search and Examination
- 2017-12-21 MA MA047121A patent/MA47121A/fr unknown
-
2019
- 2019-06-17 CO CONC2019/0006320A patent/CO2019006320A2/es unknown
-
2020
- 2020-10-30 US US17/084,881 patent/US11851495B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019011750A2 (pt) | 2019-10-29 |
| EP3360898A1 (fr) | 2018-08-15 |
| JP7196076B2 (ja) | 2022-12-26 |
| EP3559040A2 (fr) | 2019-10-30 |
| CO2019006320A2 (es) | 2019-06-28 |
| CN110582513B (zh) | 2023-11-14 |
| PE20191251A1 (es) | 2019-09-18 |
| JP2020501586A (ja) | 2020-01-23 |
| CN110582513A (zh) | 2019-12-17 |
| US20210095038A1 (en) | 2021-04-01 |
| MX2019007511A (es) | 2019-09-04 |
| KR102651761B1 (ko) | 2024-03-26 |
| MX391650B (es) | 2025-03-21 |
| TW201835102A (zh) | 2018-10-01 |
| AU2017384687A1 (en) | 2019-06-13 |
| KR20190099223A (ko) | 2019-08-26 |
| US20180179287A1 (en) | 2018-06-28 |
| AU2017384687B2 (en) | 2025-01-23 |
| WO2018115231A2 (fr) | 2018-06-28 |
| WO2018115231A3 (fr) | 2018-08-02 |
| US11851495B2 (en) | 2023-12-26 |
| TWI790219B (zh) | 2023-01-21 |
| EP3559040B1 (fr) | 2026-04-08 |
| US10858438B2 (en) | 2020-12-08 |
| EA201991480A1 (ru) | 2020-01-15 |
| CA3046591A1 (fr) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| EP3621592A4 (fr) | Polythérapies pour le traitement du cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA41555A (fr) | Polythérapie pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3285773A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP3397963A4 (fr) | Inhibition de mapk p38 pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| EP3452060A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP3436002A4 (fr) | Combinaisons pharmaceutiques pour le traitement du cancer | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| MA45429A (fr) | Polythérapie pour le traitement du cancer | |
| EP3351189A4 (fr) | Instrument de traitement pour endoscope | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3400010A4 (fr) | Combinaisons anti-her2 pour le traitement des tumeurs | |
| EP3362066A4 (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3400011A4 (fr) | Combinaisons anti-cd20 pour le traitement des tumeurs | |
| EP3383407A4 (fr) | Conjugués de cytarabine pour le traitement du cancer | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| EP3335041A4 (fr) | Biomarqueurs pour le traitement de la pelade | |
| EP3331510A4 (fr) | Thérapies combinatoires pour le traitement du cancer | |
| MA41123A (fr) | Polythérapie pour le traitement du cancer | |
| EP3347025A4 (fr) | Méthodes et compositions pour le traitement du cancer |